报价延迟最少15分钟:2025/09/17 07:40 EDT
盘前时段
|
||||
|
0.3675 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.37
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.86/-0.55
|
|
企业价值
13.46M
|
| 资产负债 |
|
每股账面净值
0.05
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.63M
|
|
每股收益
0.04
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/17 07:40 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets. |
